Evidence map›Paper›PMID 34699587›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments.

Ethel D Weld, Jacqueline Astemborski, Gregory D Kirk, Mark S Sulkowski, Stephanie Katz, Richard Rothman, Sunil S Solomon, Gail V Matthews, Yu Hsiang Hsieh, Malvika Verma and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Prospects for Long-Acting Treatments for Hepatitis C.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Ethel D WeldDepartment of Medicine, Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-9519-3348
Jacqueline AstemborskiDepartment of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gregory D KirkDepartment of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mark S SulkowskiDepartment of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Stephanie KatzDepartment of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Richard RothmanDepartment of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sunil S SolomonDepartment of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gail V MatthewsThe University of New South Wales, Sydney, Australia.
Yu Hsiang HsiehDepartment of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Malvika VermaDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Giovanni TraversoDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Susan SwindellsDepartment of Internal Medicine, Section of Infectious Diseases, The University of Nebraska Medical Center, Omaha, Nebraska, USA.
Andrew OwenDepartment of Pharmacology and Therapeutics, Centre of Excellence in Long acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdomand.ORCID 0000-0002-9819-7651
Jordan FeldThe Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Charles FlexnerDepartment of Medicine, Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shruti H MehtaDepartment of Epidemiology, Division of Infectious Disease Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
David L ThomasDepartment of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USBrigham and Women's Hospital · USMassachusetts Institute of Technology · USUniversity Health Network · CAUniversity of Liverpool · GBUniversity of Nebraska Medical Center · USUNSW Sydney · AU

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)R24AI118397 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner · 2015 to 2026
$9.4M
Individual, Network and Spatial Drivers of HIV and HCV among PWID in IndiaR01DA041736 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SOLOMON, SUNIL SUHAS · 2016 to 2021
$5.0M
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugsR01DA048063 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta, David L Thomas · 2019 to 2026
$4.2M
A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (the REACT Study)R01DA040506 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI MATTHEWS, GAIL · 2015 to 2019
$3.7M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
Patient-Oriented Research and Mentorship in HIV and Non-Communicable DiseasesK24AI118591 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 2015 to 2019
$766k
NIAID NIH HHS K24 AI118591NIAID NIH HHS P30 AI094189NIAID NIH HHS R24 AI118397NIDA NIH HHS K24 DA034621NIDA NIH HHS R01 DA040506NIDA NIH HHS R01 DA041736NIDA NIH HHS R01 DA048063NIDA NIH HHS U01 DA036297
6 · The paper itself

Abstract

backgroundWhereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment.

methodsA cross-sectional, 43-question survey was administered to 1457 individuals with or at risk of HCV at 28 sites in 9 countries to assess comparative interest in a variety of long-acting strategies in comparison with oral pills.

resultsAmong HCV-positive participants, 37.7% most preferred an injection, 5.6% an implant, and 6% a gastric residence device, as compared with 50.8% who stated they would most prefer taking 1-3 pills per day. When compared directly to taking pills, differences were observed in the relative preference for an injection based on age (P<.001), location (P<.001), and prior receipt of HCV treatment (P=.005) but not sex. When an implant was compared with pills, greater preference was represented by women (P=.01) and adults of younger ages (P=.01 per 5 years). Among participants without HCV, 49.5% believed that injections are stronger than pills and 34.7% preferred taking injections to pills. Among those at-risk participants who had received injectable medications in the past, 123 of 137 (89.8%) expressed willingness to receive one in the future.

conclusionsThese data point to high acceptability of long-acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C.

Indexed as

HepacivirusHepatitis CAdultAntiviral AgentsChild, PreschoolCross-Sectional StudiesFemaleHumansAntiviral AgentsActing Treatments Patient Preferences Medication Acceptability Novel Drug Delivery MethodsHepatitis C Long

Identifiers

PMID34699587
PMCPMC9402695
OpenAlexW3210374656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.